申请人:Taisho Pharmaceutical Co. Ltd.
公开号:EP1650202A1
公开(公告)日:2006-04-26
A 4,5-dihydronaphtho[1,2-b]thiophene derivative expressed by the formula:
(wherein R1 is a C1 to C10 1-hydroxyalkyl group or a C1 to C10 acyl group, and R2 and R3 separately substitute in the 6-, 7-, 8-, or 9-positions, and are each independently a hydrogen atom, a halogen atom, a C1 to C10 alkyl group, a hydroxy group, a C1 to C10 alkoxy group, a C1 to C5 alkenyloxy group, a C1 to C5 alkynyloxy group, a benzyloxy group, or the like, provided that when R1 is an acyl group and R2 is a hydrogen atom, then R3 is neither a hydrogen atom nor an acetyl group), or a pharmaceutically acceptable salt thereof. This is a novel compound that is effective in reducing triglyceride levels in the liver and reducing blood glucose levels.
一种 4,5-二氢萘并[1,2-b]噻吩衍生物,其化学式为
(其中 R1 是 C1 至 C10 的 1-羟基烷基或 C1 至 C10 的酰基,R2 和 R3 分别取代 6、7、8 或 9 位,且各自独立地是氢原子、卤素原子、C1 至 C10 的烷基、羟基、C1 至 C10 的烷氧基、C1 至 C5 的烯氧基、C1 至 C5 的炔氧基、C1 至 C5 的炔烃氧基)、C1~C5烯氧基、C1~C5炔氧基、苄氧基或类似基团,条件是当 R1 是酰基而 R2 是氢原子时,R3 既不是氢原子也不是乙酰基),或其药学上可接受的盐。这是一种新型化合物,可有效降低肝脏中的甘油三酯水平并降低血糖水平。